Allows Patients With Exceptional Early Responses To Double Treatment Interval With Guselkumab With No Loss In Disease Control, Trial Shows. August 06, 2024 edition of American Academy of Dermatology’s Dermatology Daily

Immune checkpoint inhibitors (ICIs) are a mainstay of immunotherapy for many cancer types — including breast, colon, liver, lung, skin, stomach, and rectal — but cancer care often brings challenging skin side effects that patients (and even physicians) may not expect.

Our study does confirm that patients with MCC are at higher risk for developing other cancers,” study author Lisa C. Zaba, MD, PhD, associate professor of dermatology and director of the Merkel cell carcinoma multidisciplinary clinic, Stanford (Calif.) Cancer Center, said in an interview. “MCC is a highly malignant cancer with a 40% recurrence risk.

Merkel cell carcinoma isn’t as common as other types of skin cancers, like basal cell carcinoma or melanoma, and tends to be more aggressive."

UW Dermatology’s Nghiem Lab Research Team, and collaborators from the Fred Hutchinson Cancer Center and Stanford Medicine, whose recent proposal was selected to receive a two-year $391,280 grant by the Kuni Foundation

Current evidence-based treatment guidelines for Merkel cell carcinoma - Dermatology Times

Lisa Zaba, MD, PhD, FAAD, explains the data behind the clinical trials on using circulating tumor DNA for merkel cell carcinoma (MCC)- Dermatology Times

A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.

Managing skin issues and immunotherapy.

“You should talk to the physician you see for psoriasis treatment to [get their input] and determine if you are on an immunosuppressive medication prior to getting the booster shot,”